» Articles » PMID: 21547550

Multiple Receptor Conformation Docking and Dock Pose Clustering As Tool for CoMFA and CoMSIA Analysis - a Case Study on HIV-1 Protease Inhibitors

Overview
Journal J Mol Model
Publisher Springer
Specialty Molecular Biology
Date 2011 May 7
PMID 21547550
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple receptors conformation docking (MRCD) and clustering of dock poses allows seamless incorporation of receptor binding conformation of the molecules on wide range of ligands with varied structural scaffold. The accuracy of the approach was tested on a set of 120 cyclic urea molecules having HIV-1 protease inhibitory activity using 12 high resolution X-ray crystal structures and one NMR resolved conformation of HIV-1 protease extracted from protein data bank. A cross validation was performed on 25 non-cyclic urea HIV-1 protease inhibitor having varied structures. The comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) models were generated using 60 molecules in the training set by applying leave one out cross validation method, r (loo) (2) values of 0.598 and 0.674 for CoMFA and CoMSIA respectively and non-cross validated regression coefficient r(2) values of 0.983 and 0.985 were obtained for CoMFA and CoMSIA respectively. The predictive ability of these models was determined using a test set of 60 cyclic urea molecules that gave predictive correlation (r (pred) (2) ) of 0.684 and 0.64 respectively for CoMFA and CoMSIA indicating good internal predictive ability. Based on this information 25 non-cyclic urea molecules were taken as a test set to check the external predictive ability of these models. This gave remarkable out come with r (pred) (2) of 0.61 and 0.53 for CoMFA and CoMSIA respectively. The results invariably show that this method is useful for performing 3D QSAR analysis on molecules having different structural motifs.

Citing Articles

Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.

Yadav D, Paliwal S, Yadav R, Pal M, Pandey A PLoS One. 2012; 7(11):e48942.

PMID: 23145032 PMC: 3493599. DOI: 10.1371/journal.pone.0048942.

References
1.
McGovern D, Mosier P, Roth B, Westkaemper R . CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity. J Mol Graph Model. 2010; 28(7):612-25. PMC: 2859180. DOI: 10.1016/j.jmgm.2009.12.008. View

2.
CARLSON H, Masukawa K, Rubins K, Bushman F, Jorgensen W, Lins R . Developing a dynamic pharmacophore model for HIV-1 integrase. J Med Chem. 2000; 43(11):2100-14. DOI: 10.1021/jm990322h. View

3.
Lam P, Jadhav P, Eyermann C, Hodge C, Ru Y, Bacheler L . Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science. 1994; 263(5145):380-4. DOI: 10.1126/science.8278812. View

4.
Klebe G, Abraham U, Mietzner T . Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem. 1994; 37(24):4130-46. DOI: 10.1021/jm00050a010. View

5.
Hodge C, Aldrich P, Bacheler L, Chang C, Eyermann C, Garber S . Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996; 3(4):301-14. DOI: 10.1016/s1074-5521(96)90110-6. View